These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 19850448)

  • 41. Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).
    Besi E; Boniface DR; Cregg R; Zakrzewska JM
    J Headache Pain; 2015; 16():563. PubMed ID: 26335440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Seizure deterioration in women treated with oxcarbazepine during pregnancy.
    Petrenaite V; Sabers A; Hansen-Schwartz J
    Epilepsy Res; 2009 Apr; 84(2-3):245-9. PubMed ID: 19231139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
    Jang Y; Yoon S; Kim TJ; Lee S; Yu KS; Jang IJ; Chu K; Lee SK
    Sci Rep; 2021 Mar; 11(1):6370. PubMed ID: 33737678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Severe overdosage with the antiepileptic drug oxcarbazepine.
    van Opstal JM; Janknegt R; Cilissen J; L'Ortije WH; Nel JE; De Heer F
    Br J Clin Pharmacol; 2004 Sep; 58(3):329-31. PubMed ID: 15327594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
    Degen PH; Flesch G; Cardot JM; Czendlik C; Dieterle W
    Biopharm Drug Dispos; 1994 Aug; 15(6):519-26. PubMed ID: 7993989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR
    Faison S; Gomeni R; Mendes S; O'Neal W; Schwabe S; Nasser A
    Clin Pharmacol; 2020; 12():135-147. PubMed ID: 33061671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.
    Eeg-Olofsson O; Nilsson HL; Tonnby B; Arvidsson J; Grahn PA; Gylje H; Larsson C; Norén L
    J Child Neurol; 1990 Apr; 5(2):159-65. PubMed ID: 2111837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxcarbazepine.
    Schulze-Bonhage A; Homberg V
    Seizure; 2002 Jan; 11(1):73. PubMed ID: 11888266
    [No Abstract]   [Full Text] [Related]  

  • 49. [Oxcarbazepine-induced localized penile edema].
    Rallis E; Theodoridis A; Moussatou V; Papadakis P; Verros C
    J Dtsch Dermatol Ges; 2005 Oct; 3(10):786-7. PubMed ID: 16194158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
    Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
    Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial.
    Privitera M; Ficker DM
    Epilepsy Behav; 2004 Dec; 5(6):841-6. PubMed ID: 15582830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The distribution of 10-hydroxy carbazepine in blood compartments.
    Jung H; Noguez A; Mayet L; Fuentes I; González-Esquivel DF
    Biopharm Drug Dispos; 1997 Jan; 18(1):17-23. PubMed ID: 9008266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circadian carbamazepine toxicity.
    Haefeli WE; Meyer PG; Lüscher TF
    Epilepsia; 1994; 35(2):400-2. PubMed ID: 8156964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.
    Wheless JW; Phelps SJ
    J Pediatr Pharmacol Ther; 2018; 23(4):277-292. PubMed ID: 30181718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.
    Anderson GD; Saneto RP
    CNS Drugs; 2015 Aug; 29(8):669-81. PubMed ID: 26369919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers.
    Clark AM; Halvorsen MB; Braun TL; Johnson KM; Cloyd JC
    Epilepsia; 2014 Jul; 55(7):1069-76. PubMed ID: 24861853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate].
    Steinhoff BJ; Trinka E; Wendling AS
    Nervenarzt; 2011 Jun; 82(6):764-7. PubMed ID: 21052972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages.
    Steinhoff BJ; Wendling AS
    Epilepsy Res; 2009 Dec; 87(2-3):256-9. PubMed ID: 19850448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].
    Steinhoff BJ; Stefan H; Schulze-Bonhage A; Hueber R; Paulus W; Wangemann M; Elger CE
    Nervenarzt; 2012 Oct; 83(10):1292-9. PubMed ID: 22850688
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.